Table 3.
Effects of hypothalamic rAAV-Lep gene therapy on cancellous bone histomorphometry at 18 weeks post-vector administration (Experiment 3).
| Endpoint | Baseline | Non-Treated | rAAV-GFP | rAAV-LEP | ANOVA P< |
|---|---|---|---|---|---|
| Histomorphometry | |||||
| Proximal tibia metaphysis (cancellous bone) | |||||
| Bone Area/tissue area (%) | 25.5 ± 1.4 | 18.8 ± 1.7a* | 13.4 ± 1.6a | 17.7 ± 2.1a | 0.001 |
| Trabecular number (mm−1) | 4.5 ± 0.6 | 3.2 ± 0.3a | 2.6 ± 0.3a | 3.4 ± 0.3a | 0.001 |
| Trabecular thickness (μm) | 57 ± 3 | 61 ± 3 | 49 ± 3.6a* | 52 ± 2 | 0.029 |
| Trabecular separation (μm) | 171 ± 11 | 289 ± 52 | 342 ± 57a | 263 ± 32 | 0.046 |
| Mineralizing perimeter/bone perimeter (%) | 6.7 ± 1.1 | 4.8 ± 0.7 | 4.7 ± 1.0 | 6.9 ± 1.3 | 0.313 |
| Mineral apposition rate (μm/d) | 0.92 ± 0.05 | 0.50 ± 0.05 | 0.84 ± 0.06 | 0.86 ± 0.06 | 0.736 |
| Bone formation rate (μm2/μm/d) | 24 ± 5 | 16 ± 3 | 14 ± 1 | 22 ± 5 | 0.200 |
Mean ± SE
a
Different from baseline, P<0.05
a*
P<0.1.
b
Different from non-treated control, P<0.05
c
Different from rAAV-GFP, P<0.05